USPTO Examiner BROWE DAVID - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18977672WOUND HEALING DRESSINGS AND FORMULATIONS AND METHODS OF USE THEREOFDecember 2024February 2026Allow1521YesNo
18842531SOFTGEL CAPSULES AND A METHOD FOR PREPARING THE SOFTGEL CAPSULESAugust 2024July 2025Allow1120NoNo
18731812AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATIONJune 2024March 2026Abandon2111NoNo
18673405CELLULOSE NANOCRYSTAL-BASED EMULSIONS AND USES THEREOFMay 2024October 2025Allow1711NoNo
18660885BLETILLA STRIATA POLYSACCHARIDE IRON COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2024March 2025Abandon1011NoNo
18653604COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLSMay 2024January 2026Allow2111NoNo
18602984DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOFMarch 2024November 2025Allow2040YesNo
18602972DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOFMarch 2024January 2026Allow2240NoNo
18417945NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSJanuary 2024December 2024Allow1021YesNo
18417989NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSJanuary 2024May 2025Abandon1621NoNo
18523274PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBNovember 2023April 2025Abandon1611NoNo
18387552PYRIDINO-2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow401NoNo
18373774COMBINATION THERAPYSeptember 2023June 2025Abandon2101NoNo
18458973COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLSAugust 2023March 2024Allow711YesNo
18457738PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITORAugust 2023June 2025Abandon2201NoNo
18233210NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSAugust 2023May 2025Abandon2141NoNo
18355684AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATIONJuly 2023December 2024Abandon1721NoNo
18259668COMPOSITION COMPRISING MICROCOCCUS LUTEUS-DERIVED EXTRACELLULAR VESICLE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASEJune 2023February 2026Abandon3101NoNo
18211746Sustained Release Compositions Comprising LiothyronineJune 2023September 2025Abandon2721NoNo
18330402Ciliated protozoan with the effect of promoting plant seed germination and seedling growthJune 2023March 2024Allow1020YesNo
18206290METHODS OF TREATING B-CELL PROLIFERATIVE DISORDERJune 2023September 2023Allow410YesNo
18330333MODIFIED IMMUNE-MODULATING PARTICLESJune 2023August 2025Abandon2601NoNo
18203759METHODS OF TREATING B-CELL PROLIFERATIVE DISORDERMay 2023November 2023Allow510YesNo
18250377DIRECT DELIVERY OF VITAMINS TO INHIBIT MICROBIAL PATHOGENSApril 2023February 2026Abandon3301NoNo
18138493ANTIMICROBIAL COMPOSITIONApril 2023November 2025Allow3141NoNo
18121826METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPYMarch 2023April 2025Abandon2501NoNo
18184228CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLESMarch 2023December 2024Allow2211NoNo
18177019METHODS FOR TREATMENT OF POST-SURGERY LAXITY OF TENDONS AND TENDON REPAIRMarch 2023March 2026Abandon3621NoNo
18173230THEAFLAVIN COMPOSITION CAPABLE OF PROMOTING WOUND HEALING AS WELL AS PREPARATION METHOD AND USE THEREOFFebruary 2023July 2024Abandon1721NoNo
18172855PHARMACEUTICAL COMPOSITIONFebruary 2023November 2025Abandon3321YesNo
18021078CD47 BINDER AND LIPOSOME COMPLEX FOR CANCER TREATMENTFebruary 2023February 2026Abandon3601NoNo
18105285Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host DiseaseFebruary 2023May 2024Allow1521NoNo
18163041NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERFebruary 2023June 2025Allow2821NoNo
18098938METHODS OF TREATING B-CELL PROLIFERATIVE DISORDERJanuary 2023April 2023Allow301NoNo
18003184Hydrophilic Degradable Microspheres for Delivering BuprenorphineDecember 2022December 2025Abandon3601NoNo
18064767SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE ,AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTIONDecember 2022June 2025Abandon3011NoNo
18009623COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS USING HARRYFLINTIA ACETISPORADecember 2022December 2025Abandon3601NoNo
18073612METHODS FOR TREATING CANCERS BY USING NANOFRAMES OF PRUSSIAN BLUE OR AN ANALOGUE THEREOF AND ITS PRODUCTION METHODSDecember 2022November 2025Allow3521NoNo
18072747NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOFDecember 2022February 2025Allow2621NoNo
17925460TABLET COMPRISING OPICAPONENovember 2022December 2025Abandon3711NoNo
17977917SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHEROctober 2022January 2024Abandon1420YesNo
17973749PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERYOctober 2022November 2024Abandon2501NoNo
17917642BINDEROctober 2022March 2026Abandon4101NoNo
17915170ORAL DELIVERY SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINESeptember 2022November 2025Abandon3801NoNo
17946237METHOD OF TREATMENT USING SYNERGISTIC DIETARY SUPPLEMENTS TO RELIEVE MOOD FLUCTUATIONS, SKIN BLEMISHES, REDUCED ENERGY LEVELS, AND/OR DIETARY CRAVINGS LINKED TO HORMONAL FLUCTUATIONS OR THE MENSTRUAL CYCLESeptember 2022January 2026Abandon4011NoNo
17893664COMPOSITION FOR CROP CARE AND PROTECTIONAugust 2022November 2024Abandon2601NoNo
17798932NATURAL C12-15 ALKYL BENZOATESAugust 2022August 2025Abandon3641YesYes
17885105PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBAugust 2022December 2023Abandon1721NoNo
17882014DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOFAugust 2022March 2024Abandon2030YesNo
17866877PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBJuly 2022May 2024Abandon2221YesYes
17758163FLOATING DRUG DELIVERY SYSTEMS COMPRISING CANNABINOIDSJune 2022June 2025Abandon3601NoNo
17850088COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONSJune 2022August 2023Abandon1412NoNo
17786114ANTIMICROBIAL COMPOSITIONSJune 2022July 2025Abandon3701NoNo
17824518PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBMay 2022December 2023Abandon1931NoNo
17745284ANTIOXIDANT AND ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING THEM TO PROTECT SKIN OR TREAT OR PREVENT INFECTIONSMay 2022October 2025Abandon4101NoNo
17776740METHOD FOR INCREASING LONGEVITY AND/OR BUD OPENING OF CUT FLOWERSMay 2022July 2025Allow3821YesNo
17737929COMPOSITIONS AND METHODS FOR KELOIDLESS HEALINGMay 2022October 2024Abandon2901NoNo
17736386CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLESMay 2022December 2022Allow811NoNo
17731920DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATORApril 2022May 2025Abandon3711NoNo
17732080OIL-IN-WATER EMULSION OF MOMETASONEApril 2022January 2025Abandon3311NoNo
17721909SURFACE-TREATING WOOD TO PREVENT DISCOLORATIONApril 2022June 2024Abandon2601NoNo
17713596THERAPEUTIC HYDROGELSApril 2022March 2025Allow3521NoNo
17703427GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEMMarch 2022December 2023Abandon2022YesNo
17699960SEEDING FORMULATION FOR WOODY PLANTS AND PRE-TREATMENT OF LAND SURFACESMarch 2022July 2025Abandon4021YesNo
17753783SOLVENT DISPERSION FORMULATION CONTAINING A SULFOPOLYMERMarch 2022August 2025Abandon4101NoNo
17678427CONCENTRATED LIQUID COMPOSITIONS OF UREASE INHIBITORS FOR NITROGEN SOURCESFebruary 2022August 2025Allow4250YesNo
17675409Surfactant Systems for Zinc Containing CompositionsFebruary 2022February 2026Abandon4821YesYes
17578844METHODS AND COMPOSITIONS FOR USING CINNAMALDEHYDE AND ZINC FOR WEIGHT MANAGEMENTJanuary 2022December 2024Abandon3521NoNo
17570596FUNGAL VOLATILE ORGANIC COMPOUND ENHANCES PLANT GROWTH CHARACTERISTICSJanuary 2022January 2026Abandon4941NoNo
17645244PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITORDecember 2021October 2022Abandon1001NoNo
17555277STABILIZED LIQUID FORMATIONS CONTAINING PICOSULFATEDecember 2021September 2025Allow4520NoYes
17553200PRESSURIZED METERED DOSE INHALERS AND METHOD OF MANUFACTUREDecember 2021February 2026Abandon5021YesYes
17540965Inorganic Nitrite to Improve Cardiopulmonary HemodynamicsDecember 2021March 2024Allow2720YesNo
17521928COMPOSITION FOR IMPROVING SKIN CONDITIONSNovember 2021January 2024Abandon2710NoNo
17518415METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUNDNovember 2021November 2025Abandon4821NoNo
17505902ANTIFUNGAL COMPOSITION HAVING EXCELLENT ANTIFUNGAL ACTIVITY EVEN AT LOW TEMPERATUREOctober 2021December 2024Allow3840NoNo
17503325PENICILLIUM SIMPLICISSIMUM SP. NL-Z1 STRAIN FOR PROMOTING GROWTH OF ROOT NODULES AND INCREASING ABUNDANCE OF PROBIOTIC MICROORGANISM POPULATIONOctober 2021December 2025Abandon5011NoNo
17604282ORAL DELIVERY SYSTEMS BASED ON IN SITU FORMING PROTEIN/POLYSACCHARIDE COACERVATESOctober 2021April 2023Allow1831YesNo
17501519TABLETS FOR ORAL SUSPENSION CONTAINING RIVAROXABANOctober 2021April 2025Abandon4231YesYes
17448450METHODS FOR TREATMENT OF POST-SURGERY LAXITY OF TENDONS AND TENDON REPAIRSeptember 2021June 2023Abandon2121YesNo
17480481METHODS AND APPARATUS FOR TREATING A WOUNDSeptember 2021January 2024Abandon2811NoNo
17475489SUSTAINED RELEASE BUPRENORPHINE MICROSPHERES (SRBM) AND METHODS OF USE THEREOFSeptember 2021November 2023Abandon2610NoNo
17471524NEW ALKYNYL-SUBSTITUTED 3-PHENYLPYRROLIDINE-2,4-DIONES AND USE THEREOF AS HERBICIDESSeptember 2021October 2023Abandon2501NoNo
17463369CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKINGAugust 2021February 2024Abandon2931NoYes
17398960Cosmetic Skin Cream and MedicineAugust 2021June 2024Abandon3411NoNo
17388453CONTAINERIZED LIQUID FORMULATIONSJuly 2021July 2025Allow4731NoNo
17378041SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONSJuly 2021February 2023Abandon1931YesNo
17422448A METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION COMPRISING NEFOPAM AND ACETAMINOPHEN, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREBYJuly 2021March 2025Abandon4451YesNo
17373711RADIATION SENSITIZER OR ANTI-CANCER CHEMOTHERAPY SENSITIZERJuly 2021February 2024Abandon3111NoNo
17372403INTRANASAL NANO INDUCER FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND METHOD THEREOFJuly 2021October 2024Abandon4021YesNo
16973000CHITOSAN GELS (A) CONTAINING METAL NANOPARTICLES OF COPPER, SILVER AND ANTIBIOTICS (CIPROFLOXACIN, CEFOTAXIME, GENTAMICIN AND CLOXACILLIN)July 2021August 2024Abandon4401NoNo
17357058Fulvic Acid Sterilization Deodorant As Well As Preparation Method and Application ThereofJune 2021December 2024Abandon4221NoNo
17342645SUSTAINED RELEASE COMPOSITIONS COMPRISING LIOTHYRONINEJune 2021December 2023Allow3061YesNo
17303736COMPOSITION AND METHOD TO PREVENT PATHOGEN TRANSMISSION THROUGH ALTERING SALIVAJune 2021May 2024Abandon3511NoNo
17331505METHODS OF ADMINISTERING ELAGOLIX IN ASSOCIATION WITH ARTIFICIAL REPRODUCTIVE TECHNOLOGIESMay 2021December 2022Abandon1921YesNo
17327702METHODS OF TREATING EYE DISEASE WITH TOBRAMYCIN-RELATED COMPOSITIONSMay 2021November 2022Allow1831YesNo
17302509Personal Care Composition with Zinc Phosphate ActiveMay 2021October 2024Abandon4121NoNo
17306442TOPICALLY-APPLIED PROBIOTIC TO TREAT DYSBIOSIS IN THE SKIN MICROBIOME OF PETS AND OTHER ANIMALSMay 2021November 2023Abandon3010NoNo
17224009USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERSApril 2021November 2023Abandon3101NoNo
17222703BIODEGRADABLE DRUG DELIVERY COMPOSITIONApril 2021September 2023Abandon3001NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BROWE, DAVID.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
67
Examiner Affirmed
40
(59.7%)
Examiner Reversed
27
(40.3%)
Reversal Percentile
63.5%
Higher than average

What This Means

With a 40.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
189
Allowed After Appeal Filing
42
(22.2%)
Not Allowed After Appeal Filing
147
(77.8%)
Filing Benefit Percentile
29.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BROWE, DAVID - Prosecution Strategy Guide

Executive Summary

Examiner BROWE, DAVID works in Art Unit 1617 and has examined 742 patent applications in our dataset. With an allowance rate of 22.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner BROWE, DAVID's allowance rate of 22.0% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BROWE, DAVID receive 3.23 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BROWE, DAVID is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +30.6% benefit to allowance rate for applications examined by BROWE, DAVID. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 5.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.6% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 19.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 44.2% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 24.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.5% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.